contact us
subTop TechOffers
  • Non-adherence to tuberculosis (TB) therapy has significant public health implications due to persistent infectivity, as well as resistance mutations.
  • The current system of Directly Observed Therapy (DOT) involves daily clinic visits for at least 6 months so a healthcare worker can observe the patient take each pill.
  • This is not only resource-heavy, commuting may potentially expose healthy commuters to TB, and waiting in the polyclinic may expose sick and immunosuppressed patients to TB
  • Being compliant to DOTs is also severely restrictive of the patient’s freedom, as well as an economic and mental drain for the patients

 

Market Impact
  • In 2011, there were 1,533 new cases of TB reported among Singapore residents.
  • We have extrapolated that providing DOT at polyclinics would cost over $3.9 million per year in Singapore
  • There are 5.5 million cases of active TB in Asia each year

 

Technology Description
  • The invention is a smartphone app to remotely implement the Directly Observed Treatment, Short-Course (DOTS) method of tuberculosis (TB) treatment.
  • Patients can use the app to capture a video of themselves taking the prescribed pill and then upload it into a cloud.
  • The app can automatically detect pill consumption using movement recognition.
  • It also has a money transfer feature to pay patients after uploads for incentivizing patients.

 

Development Status
  • The MIST system has been piloted in 24 healthy volunteers who were prescribed a daily multivitamin supplement for 2 months and had adherence supplemented with the MIST system throughout.
  • Team is looking to validate app in Bangkok for HIV patients

 

Current IP Position: Patent Pending (PCT/SG2016/050119 filed on 15 March 2016)

 

Future Progress

Seeking IP licensing to SME/MNC operating in Stents/Stent Coating OR Collaborative technology development with industry partners.

 

Dr James Molton / National University Health System

 

targetGroup_clinicianInnovators
targetGroup_ResearchAdministrator
targetGroup_IndustryPartner
targetGroup_Investor